Cargando…

Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge

INTRODUCTION: Almost 50% of the 17.5 million deaths worldwide from cardiovascular disease have been associated with systemic arterial hypertension (SAH). Into this scenario, Pharmaceutical Care (PC) has been inserted in order to improve the management of SAH and reduce its risks. OBJECTIVE: To evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazarim, Maurílio de Souza, de Freitas, Osvaldo, Penaforte, Thais Rodrigues, Achcar, Angela, Pereira, Leonardo Régis Leira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909302/
https://www.ncbi.nlm.nih.gov/pubmed/27304922
http://dx.doi.org/10.1371/journal.pone.0155204
_version_ 1782437817115213824
author Cazarim, Maurílio de Souza
de Freitas, Osvaldo
Penaforte, Thais Rodrigues
Achcar, Angela
Pereira, Leonardo Régis Leira
author_facet Cazarim, Maurílio de Souza
de Freitas, Osvaldo
Penaforte, Thais Rodrigues
Achcar, Angela
Pereira, Leonardo Régis Leira
author_sort Cazarim, Maurílio de Souza
collection PubMed
description INTRODUCTION: Almost 50% of the 17.5 million deaths worldwide from cardiovascular disease have been associated with systemic arterial hypertension (SAH). Into this scenario, Pharmaceutical Care (PC) has been inserted in order to improve the management of SAH and reduce its risks. OBJECTIVE: To evaluate the outcomes and healthcare assistance achieved after discharge of hypertension patients from the PC program. METHODS: This is a quasi-experimental study with historical controls. Retrospective data collection from 2006 to 2012 was begun in 2013 and included a PC program performed over one year. PC was performed in two basic units of the public health system in Ribeirão Preto-SP, Brazil, where the pharmacist followed up 104 hypertensive patients. The clinical indicators of systolic (SBP) and diastolic blood pressure (DBP), triglycerides, total-cholesterol, high and low density lipoprotein cholesterol were collected, as well as care indicators related to the number of consultations (basic, specialized and emergency care) and antihypertensive drugs used. The coronary risk of patients by the Framingham risk score was also calculated. For the analysis, the data were divided into three periods, 2006–2008 as pre-PC, 2009 as PC and 2010–2012 as post-PC. RESULTS: In the pre-PC period, 54.4%, 79.0% and 27.3% of patients presented satisfactory levels of SBP, DBP and total-cholesterol, respectively. In the post-PC period, the percentages were 93.0% for SBP and DBP [p <0.001] and 60.6% for total-cholesterol [p <0.001]. The average number of consultations per patient/year in primary care was 1.66 ± 1.43 and 2.36 ± 1.73, [p = 0.012]; and for emergency care was 1.70 ± 1.43 and 1.06 ± 0.81, [p = 0.002] in the pre-PC and post-PC periods, respectively. The pre-PC Framingham risk in the last year was 14.3% ± 10.6 and the average post-PC was 10.9% ± 7.9. CONCLUSION: PC was effective in the control of blood pressure and total-cholesterolafter discharge of the hypertensive patients from PC program.
format Online
Article
Text
id pubmed-4909302
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49093022016-07-06 Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge Cazarim, Maurílio de Souza de Freitas, Osvaldo Penaforte, Thais Rodrigues Achcar, Angela Pereira, Leonardo Régis Leira PLoS One Research Article INTRODUCTION: Almost 50% of the 17.5 million deaths worldwide from cardiovascular disease have been associated with systemic arterial hypertension (SAH). Into this scenario, Pharmaceutical Care (PC) has been inserted in order to improve the management of SAH and reduce its risks. OBJECTIVE: To evaluate the outcomes and healthcare assistance achieved after discharge of hypertension patients from the PC program. METHODS: This is a quasi-experimental study with historical controls. Retrospective data collection from 2006 to 2012 was begun in 2013 and included a PC program performed over one year. PC was performed in two basic units of the public health system in Ribeirão Preto-SP, Brazil, where the pharmacist followed up 104 hypertensive patients. The clinical indicators of systolic (SBP) and diastolic blood pressure (DBP), triglycerides, total-cholesterol, high and low density lipoprotein cholesterol were collected, as well as care indicators related to the number of consultations (basic, specialized and emergency care) and antihypertensive drugs used. The coronary risk of patients by the Framingham risk score was also calculated. For the analysis, the data were divided into three periods, 2006–2008 as pre-PC, 2009 as PC and 2010–2012 as post-PC. RESULTS: In the pre-PC period, 54.4%, 79.0% and 27.3% of patients presented satisfactory levels of SBP, DBP and total-cholesterol, respectively. In the post-PC period, the percentages were 93.0% for SBP and DBP [p <0.001] and 60.6% for total-cholesterol [p <0.001]. The average number of consultations per patient/year in primary care was 1.66 ± 1.43 and 2.36 ± 1.73, [p = 0.012]; and for emergency care was 1.70 ± 1.43 and 1.06 ± 0.81, [p = 0.002] in the pre-PC and post-PC periods, respectively. The pre-PC Framingham risk in the last year was 14.3% ± 10.6 and the average post-PC was 10.9% ± 7.9. CONCLUSION: PC was effective in the control of blood pressure and total-cholesterolafter discharge of the hypertensive patients from PC program. Public Library of Science 2016-06-15 /pmc/articles/PMC4909302/ /pubmed/27304922 http://dx.doi.org/10.1371/journal.pone.0155204 Text en © 2016 Cazarim et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cazarim, Maurílio de Souza
de Freitas, Osvaldo
Penaforte, Thais Rodrigues
Achcar, Angela
Pereira, Leonardo Régis Leira
Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge
title Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge
title_full Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge
title_fullStr Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge
title_full_unstemmed Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge
title_short Impact Assessment of Pharmaceutical Care in the Management of Hypertension and Coronary Risk Factors after Discharge
title_sort impact assessment of pharmaceutical care in the management of hypertension and coronary risk factors after discharge
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909302/
https://www.ncbi.nlm.nih.gov/pubmed/27304922
http://dx.doi.org/10.1371/journal.pone.0155204
work_keys_str_mv AT cazarimmauriliodesouza impactassessmentofpharmaceuticalcareinthemanagementofhypertensionandcoronaryriskfactorsafterdischarge
AT defreitasosvaldo impactassessmentofpharmaceuticalcareinthemanagementofhypertensionandcoronaryriskfactorsafterdischarge
AT penafortethaisrodrigues impactassessmentofpharmaceuticalcareinthemanagementofhypertensionandcoronaryriskfactorsafterdischarge
AT achcarangela impactassessmentofpharmaceuticalcareinthemanagementofhypertensionandcoronaryriskfactorsafterdischarge
AT pereiraleonardoregisleira impactassessmentofpharmaceuticalcareinthemanagementofhypertensionandcoronaryriskfactorsafterdischarge